More than half of patients alive two years after receiving CAR-T...
A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma (DLBCL) reported 51...
MD Anderson, Houston Dynamo team up for one goal: end cancer
The University of Texas MD Anderson Cancer Center and the Houston Dynamo today announced plans to work together toward one goal: end...
Peers choose MD Anderson’s Gershenwald, Hwu as new AAAS...
Two leaders in the field of melanoma treatment – a surgeon and an oncologist – from The University of Texas MD Anderson Cancer Center...
Stand Up to Cancer funds innovative approach to pancreatic cancer
Research on a new way of deploying the immune system against pancreatic cancer, an exceptionally lethal cancer that has so far...
FDA restrictions on e-cigarettes an important step to...
The University of Texas MD Anderson Cancer Center applauds new actions announced today by the U.S. Food and Drug Administration (FDA)...
Investigational drug shows promising results in Phase II...
A Phase I/II study, led by investigators at The University of Texas MD Anderson Cancer Center, reports an investigational drug called...
Immunotherapy combination and chemotherapy show encouraging...
A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent...
First UT System clinical collaboration launches between MD...
The University of Texas MD Anderson Cancer Center today formally opened a four-story facility in League City that houses new and...
Fecal transplant effective against immunotherapy-induced...
For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe...
Combination chemotherapy and immunotherapy effective in...
A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor,...